Tubers and tumors: rapamycin therapy for benign and malignant tumors

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Rapamycin and its derivatives are pharmaceuticals used in organ transplantation, cardiovascular disease, hamartomas, and cancer.
• These drugs uniquely target tumor-associated metabolic changes in cancer therapy.
• The mechanistic target of rapamycin complex 1 (mTORC1) is a key regulator of cellular metabolism.

Purpose of the Study:

• To review the role of rapamycin and its derivatives in targeting cellular metabolism.
• To highlight the significance of mTORC1 and its regulatory proteins in tumor growth and metabolism.
• To explore the potential of novel mTOR and PI3K inhibitors for therapeutic applications, especially in cancer.

Main Methods:

• Literature review of rapamycin and its derivatives.
• Analysis of the mTORC1 pathway and its upstream regulators.
• Discussion of novel therapeutic compounds targeting mTOR and PI3K.

Main Results:

• Rapamycin derivatives exploit tumor-specific metabolic alterations.
• mTORC1 pathway components (TSC, Rheb, hVps34, Rag GTPases) influence tumor growth, metabolism, and apoptosis.
• Novel compounds targeting mTOR and PI3K show promise for enhanced therapeutic efficacy.

Conclusions:

• Rapamycin and its derivatives are valuable agents targeting cellular metabolism, particularly in cancer.
• Understanding mTORC1 regulation is critical for developing effective cancer therapies.
• Targeting mTOR and PI3K pathways with novel compounds offers a promising strategy for treating various human pathologies, including cancer.